RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma

@inproceedings{Zhang2016RelANS,
  title={RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma},
  author={Mingzhi Zhang and Zijun Y. Xu-Monette and Ling Li and Ganiraju C Manyam and Carlo Visco and Alexandar Tzankov and Jing Wang and Santiago Montes-Moreno and Karen Dybkaer and April Chiu and Attilio Orazi and Youli Zu and Govind Bhagat and Kristy L Richards and E D Hsi and William W. L. Choi and J. Han van Krieken and Jooryung Huh and Maurilio Ponzoni and Andr{\'e}s J M Ferreri and Michael Boe M\oller and Ben M. Parsons and Jane N. Winter and Miguel {\'A}ngel Piris and L. Jeffrey Medeiros and Lan V. Pham and KEN. H. YOUNG},
  booktitle={Aging},
  year={2016}
}
It has been well established that nuclear factor kappa-B (NF-κB) activation is important for tumor cell growth and survival. RelA/p65 and p50 are the most common NF-kB subunits and involved in the classical NF-kB pathway. However, the prognostic and biological significance of RelA/p65 is equivocal in the field. In this study, we assessed RelA/p65 nuclear… CONTINUE READING